9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

Homepage

Search the NeLM

Medicines A-Z

Find key information about medicines by name (prototype)

Browse by Categories:

Browse by NeLM area:

BNF Category

240 library items in 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

Filter results by:

Date Published

NeLM Area

News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies

Results filtered by:

Category

9: Nutrition and blood (remove) , 9.1 Anaemias and some other blood disorders (remove) , 9.1.3 Drugs used in hypoplastic, haemolytic, and r (remove)

Sort by: Display summary:

Results 1 - 10 of 240

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next

1.

The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) program in practice: does it really inform patients and limit risk?

Source: American Journal of Kidney Diseases,
Date published: 25/04/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Adverse Drug Reactions | Food &Drug Administration (FDA) | Patient

NeLM Area:

Evidence > Medicines Management > References

Full text link (PDF)
2.

Deferiprone (Ferriprox) for iron overload

Source: Medical Letter on Drugs and Therapeutics,
Date published: 05/04/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias

NeLM Area:

Evidence > Medicines Management > References

Journal website
3.

Study identifies additional triggers of hospitalisation for VTE

Source: Circulation,
Date published: 04/04/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Adverse Drug Reactions | Venous Thromboembolism

NeLM Area:

News

Link (abstract)

Editorial (extract)
4.

FDA approves peginesatide (Omontys®) for treatment of anaemia due to CKD in adults on dialysis

Source: FDA,
Date published: 28/03/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Anaemias | Food &Drug Administration (FDA) | New drugs | Renal medicine

NeLM Area:

News

BioSpace news item

FDA press release

EMA review (NeLM news item)

EMERALD study results (NeLM report)
5.

How much are biosimilars used in Southern Italy?: A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010-2011

Source: BioDrugs,
Date published: 21/03/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Generic prescribing

NeLM Area:

Evidence > Medicines Management > References

Abstract link
6.

CADTH review: Treatment of anaemia and neutropenia in patients with chronic hepatitis C infection treated with peginterferon-ribavirin based regimens

Source: Canadian Agency for Drugs and Technologies in Health (CADTH),
Date published: 12/03/2012

Category:

5.3.1 HIV infection | 5.3.3 Viral hepatitis | 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Anaemias | Drug reviews | Hepatitis and other gastrointestinal infections | Neutropenia

NeLM Area:

News

Link
7.

Direct Healthcare Professional Communication on potential shortages of Mircera® (methoxy polyethylene glycol-epoetin beta)

Source: MHRA,
Date published: 05/03/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Haematology | Renal medicine

NeLM Area:

News

Link
8.

Horizon scanning: EMA accepts marketing authorisation application for peginesatide for symptomatic anaemia associated with chronic kidney disease

Source: PharmaLive,
Date published: 29/02/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Drugs in renal failure | European Agency for the Evaluation of Medicinal Products (EMEA) | New drugs | Renal medicine

NeLM Area:

News

Link to PharmaLive report

Link to NeLM report of EMERALD 1 and 2
9.

Deferasirox for managing iron overload in people with thalassaemia

Source: Cochrane,
Date published: 27/02/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Haematology

NeLM Area:

Evidence > Drug Specific Reviews

Link to Abstract
10.

SMC unable to recommend eculizumab (Soliris™) for atypical haemolytic uremic syndrome due to non-submission

Source: Scottish Medicines Consortium (SMC),
Date published: 14/02/2012

Category:

9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias | Drug reviews | Renal medicine | Scottish Medicines Consortium

NeLM Area:

Evidence > Drug Specific Reviews

Link

Results 1 - 10 of 240

Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next